SHR 1703
Alternative Names: SHR-1703Latest Information Update: 25 Oct 2024
Price :
$50 *
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Churg-Strauss syndrome
- Phase II Asthma
Most Recent Events
- 01 Oct 2024 Guangdong Hengrui Pharmaceutical plans a phase III trial for Asthma in China (SC) in October 2024 (NCT06653322)
- 04 Jun 2024 Guangdong Hengrui Pharmaceutical plans a phase II trial for Asthma in June 2024 (SC, Injection) (NCT06441812)
- 04 Dec 2023 Phase-III clinical trials in Granulomatosis with polyangiitis (Parenteral), prior to December 2023 (Jiangsu HengRui Medicine pipeline, December 2023)